Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose ...

Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations. Looking ...

Learn more about whether LeMaitre Vascular, Inc. or Teleflex Incorporated is a better investment based on AAII's A+ Investor ...

Fintel reports that on February 28, 2025, Barrington Research downgraded their outlook for LeMaitre Vascular (NasdaqGM:LMAT) ...

Oppenheimer has downgraded LeMaitre Vascular (NASDAQ:LMAT) to perform from outperform as its price target of $93 has been met ...

Truist Financial Corp increased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) by 21.0% during the 4th quarter, according to its most recent disclosure with the SEC. The ...

Citizens JMP raised the firm’s price target on LeMaitre (LMAT) to $113 from $100 and keeps an Outperform rating on the shares. LeMaitre’s Q4 ...

Welcome to the LeMaitre Vascular Q4 2024 Financial Results Conference Call. As a reminder, today's conference is being recorded. At this time, I would like to turn the call over to Mr. J.J ...

Barrington analyst Michael Petusky downgraded LeMaitre (LMAT) to Market Perform from Outperform without a price target following the Q4 report.

For the current quarter ending in March, LeMaitre said it expects revenue in the range of $56.7 million to $58.7 million. The company expects full-year earnings to be $2.15 to $2.32 per share, with ...

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) will likely be releasing its earnings data after the market closes on ...

BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results ...